Avinger (AVGR) Reports Q1 Loss of $1.06/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avinger, Inc. Announces Second Quarter 2016 Results
August 1, 2016 4:01 PM EDTREDWOOD CITY, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR) (the Company), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2016.
Second Quarter Highlights
Revenue of $4.7 million, a 54% increase compared to the second quarter of 2015Added 19 lumivascular accounts, the most in a single quarter, expanding the installed base of the Company's lumivascular platform to 126 accountsWhile our installed base of lumivascular accounts grew significantly in the second quarter, we experienced lower than... More
